SENS vs. TXG, TRNS, CTKB, EYPT, LAB, ALNT, QSI, AEHR, QTRX, and MASS
Should you be buying Senseonics stock or one of its competitors? The main competitors of Senseonics include 10x Genomics (TXG), Transcat (TRNS), Cytek Biosciences (CTKB), EyePoint Pharmaceuticals (EYPT), Standard BioTools (LAB), Allient (ALNT), Quantum-Si (QSI), Aehr Test Systems (AEHR), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Senseonics vs.
10x Genomics (NASDAQ:TXG) and Senseonics (NYSE:SENS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability.
10x Genomics has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Senseonics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
Senseonics has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Senseonics, indicating that it is currently the more affordable of the two stocks.
10x Genomics received 57 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 51.26% of users gave 10x Genomics an outperform vote while only 10.81% of users gave Senseonics an outperform vote.
In the previous week, 10x Genomics had 9 more articles in the media than Senseonics. MarketBeat recorded 9 mentions for 10x Genomics and 0 mentions for Senseonics. 10x Genomics' average media sentiment score of 1.11 beat Senseonics' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media.
10x Genomics has a net margin of -29.90% compared to Senseonics' net margin of -362.30%. 10x Genomics' return on equity of -25.40% beat Senseonics' return on equity.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 12.4% of Senseonics shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by company insiders. Comparatively, 3.6% of Senseonics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
10x Genomics presently has a consensus price target of $20.21, indicating a potential upside of 94.56%. Senseonics has a consensus price target of $2.00, indicating a potential upside of 170.01%. Given Senseonics' stronger consensus rating and higher possible upside, analysts clearly believe Senseonics is more favorable than 10x Genomics.
Summary
10x Genomics beats Senseonics on 12 of the 18 factors compared between the two stocks.
Get Senseonics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SENS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senseonics Competitors List
Related Companies and Tools
This page (NYSE:SENS) was last updated on 3/24/2025 by MarketBeat.com Staff
Buy SENS Stock Free SENS Stock Alerts